by Ivo De Nooijer | Oct 22, 2026 | Blog, Uncategorized
Strong science does not organise a company. Once a research project becomes a start-up, decisions about money, people, intellectual property and patient access need a clear home. This is the practical role of life sciences start-up governance. That sounds obvious. In...
by Patricia Baumgart | Aug 28, 2026 | Access by Design, Blog
PRIME, the European Medicines Agency’s (EMA) Priority Medicines (or PRIME) scheme, is a regulatory tool designed to support medicines that address unmet medical needs. For academic researchers and small development teams, using PRIME in drug development can...
by Max Verhage | Jun 30, 2026 | Blog
Strong science opens doors. A compelling compound, solid preclinical data, and a clear unmet need can secure a grant or attract initial interest. But funding socially responsible drug development from lab to patient requires more than that. Later-stage funders want...
by Vincent Van der Wel | Apr 21, 2026 | Blog
Original post: 11 Aug 2025 | Updated: 21 Apr 2026 Developing a medicine that is accessible for patients remains a big challenge, especially in areas like rare diseases or drug repurposing. Researchers publish new papers with potential treatments every day, but the...
by Max Verhage | Mar 13, 2026 | Blog
Not every promising discovery needs its own company. But making the right venture decision in socially responsible drug development is one of the most consequential choices an academic researcher, clinician, or principal investigator will face. In socially responsible...
by Max Verhage | Feb 5, 2026 | Blog
You probably recognise this situation. You have strong science, promising early data, and a clear potential to help patients. Yet the project risks stalling before it reaches the clinic. Or it moves forward in a way that promises a long and torturous road to get...
